Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.47 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 4/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CTSG | P08311 | 2/20 | 0.40 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17055358 | 0.83 | KMT2A (0.53) | KMT2AMEN1DDB1CRBNL3MBTL1 | |
| SCHEMBL8028864 | 0.81 | KMT2A (0.48) | KMT2AMEN1DDB1CRBNL3MBTL1 | |
| SCHEMBL22394885 | 0.77 | KMT2A (0.61) | KMT2AMEN1DDB1CRBNL3MBTL1 | |
| SCHEMBL16400948 | 0.76 | KMT2A (0.46) | KMT2AMEN1DDB1CRBNL3MBTL1 | |
| SCHEMBL16401189 | 0.76 | KMT2A (0.46) | KMT2AMEN1DDB1CRBNL3MBTL1 | |
| SCHEMBL16400865 | 0.75 | KMT2A (0.45) | KMT2AMEN1DDB1CRBNL3MBTL1 | |
| SCHEMBL18569534 | 0.74 | KMT2A (0.44) | KMT2AMEN1DDB1CRBNL3MBTL1 | |
| SCHEMBL3163816 | 0.73 | CASP3 (0.46) | KMT2AMEN1L3MBTL1POLBCYP2D6 | |
| SCHEMBL531434 | 0.73 | GRM2 (0.52) | KMT2AMEN1DDB1CRBNL3MBTL1 | |
| SCHEMBL17443866 | 0.72 | MEN1 (0.51) | KMT2AMEN1DDB1CRBNL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025049419-A1 | PYRAZOLYL COMPOUNDS AS EMOPAMIL BINDING PROTEIN INHIBITORS | GENZYME CORPORATION (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20250011325-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-01-09 | — | — | US | disclosed |
| EP-4472967-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| CN-118973581-A | IRAK degradation agent and application thereof | 凯麦拉医疗公司 | 2024-11-15 | — | — | CN | disclosed |
| US-12091411-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20230365562-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365562-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365562-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2023147594-A2 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023147594-A2 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-9526733-B1 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2016-12-27 | — | — | US | disclosed |
| US-9526733-B1 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2016-12-27 | — | — | US | disclosed |
| US-9469652-B2 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2016-10-18 | — | — | US | disclosed |
| US-9469652-B2 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2016-10-18 | — | — | US | disclosed |
| US-9469652-B2 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2016-10-18 | — | — | US | disclosed |
| WO-2016106029-A1 | THIENO[2,3-C]PYRROL-4-ONE DERIVATIVES AS ERK INHIBITORS | ELI LILLY AND COMPANY (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016106029-A1 | THIENO[2,3-C]PYRROL-4-ONE DERIVATIVES AS ERK INHIBITORS | ELI LILLY AND COMPANY (US) | 2016-06-30 | — | — | WO | disclosed |
| US-20160176896-A1 | ERK INHIBITORS | ELI LILLY AND COMPANY | 2016-06-23 | — | — | US | disclosed |
| US-20160176896-A1 | ERK INHIBITORS | ELI LILLY AND COMPANY | 2016-06-23 | — | — | US | disclosed |
| US-20160176896-A1 | ERK INHIBITORS | ELI LILLY AND COMPANY | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365562-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KMT2A 445/4885MEN1 4055/4885DDB1 1267/4885 |
| US-20160176896-A1 | ERK INHIBITORS | MAPK4, MAPK1, MAPK3 | KMT2A 3179/4885MEN1 3266/4885DDB1 1214/4885 |
| US-20250011325-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KMT2A 445/4885MEN1 4055/4885DDB1 1267/4885 |
| US-12091411-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | KMT2A 445/4885MEN1 4055/4885DDB1 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.